- Home
- ANTX vs KALA Comparison
ANTX vs KALA Comparison
Compare ANTX & KALA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANTX
- KALA
- Stock Information
- Founded
- ANTX 2017
- KALA 2009
- Country
- ANTX United States
- KALA United States
- Employees
- ANTX N/A
- KALA N/A
- Industry
- ANTX Biotechnology: Pharmaceutical Preparations
- KALA Biotechnology: Pharmaceutical Preparations
- Sector
- ANTX Health Care
- KALA Health Care
- Exchange
- ANTX Nasdaq
- KALA Nasdaq
- Market Cap
- ANTX 33.2M
- KALA 26.2M
- IPO Year
- ANTX 2022
- KALA 2017
- Fundamental
- Price
- ANTX $1.07
- KALA $5.82
- Analyst Decision
- ANTX Buy
- KALA Strong Buy
- Analyst Count
- ANTX 2
- KALA 3
- Target Price
- ANTX $2.00
- KALA $14.00
- AVG Volume (30 Days)
- ANTX 287.0K
- KALA 77.6K
- Earning Date
- ANTX 08-12-2025
- KALA 08-05-2025
- Dividend Yield
- ANTX N/A
- KALA N/A
- EPS Growth
- ANTX N/A
- KALA N/A
- EPS
- ANTX N/A
- KALA N/A
- Revenue
- ANTX N/A
- KALA N/A
- Revenue This Year
- ANTX N/A
- KALA N/A
- Revenue Next Year
- ANTX N/A
- KALA N/A
- P/E Ratio
- ANTX N/A
- KALA N/A
- Revenue Growth
- ANTX N/A
- KALA N/A
- 52 Week Low
- ANTX $0.87
- KALA $2.92
- 52 Week High
- ANTX $3.07
- KALA $11.20
- Technical
- Relative Strength Index (RSI)
- ANTX 45.19
- KALA 66.64
- Support Level
- ANTX $1.07
- KALA $4.36
- Resistance Level
- ANTX $1.11
- KALA $5.75
- Average True Range (ATR)
- ANTX 0.04
- KALA 0.54
- MACD
- ANTX 0.00
- KALA 0.08
- Stochastic Oscillator
- ANTX 15.04
- KALA 82.44
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology.
About KALA KALA BIO Inc.
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.